Organization · Venture Capital
DEFTA Partners
DEFTA Partners is a cross-border venture capital firm founded in 1985, focusing on early-stage investments in healthcare, biotechnology, and information and communication technology across the U.S., Japan, and Europe.
Overview
What DEFTA Partners does
What DEFTA Partners is
DEFTA Partners is a cross-border venture capital firm founded in 1985, focusing on early-stage investments in healthcare, biotechnology, and information and communication technology across the U.S., Japan, and Europe.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1985
- Approximate age
- About 41 years
- Structured capabilities
- Funder
- Last reviewed
- March 30, 2026
Official channels
Find DEFTA Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
DEFTA Partners as a funder
Investment thesis
DEFTA Partners focuses on early-stage investments in innovative technologies, particularly in healthcare and ICT, with a strong emphasis on cross-border US-Asia commercialization.
Focus narrative
DEFTA Partners primarily invests in the healthcare and ICT sectors. In healthcare, the focus is on advanced therapeutics, health ICT, and enabling technologies. In ICT, the firm emphasizes pervasive ubiquitous communications (PUC), influencing investments in embedded devices, digital TV, and online security. The organization adopts a global investment strategy, targeting opportunities across North America, Europe, Asia, and the Middle East.
Value beyond capital
DEFTA Partners adds value to its portfolio companies through strategic guidance, leveraging its extensive network across the US and Asia, and focusing on sustainable growth initiatives. The firm’s deep expertise in healthcare and ICT enables it to provide critical insights and support for technology commercialization.
Focus and fit
- Stages
- Seed · Series A · Series B
- Regions
- AsiaEuropeMENANorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 100
- Recorded notable exits
- Fortinet, Viagene, and Isis Pharmaceuticals
Portfolio context
Notable portfolio companies include: Aegle Therapeutics Corporation: A biotechnology company developing extracellular vesicles as therapy, recently awarded a grant by the U.S. Department of Defense for its product candidate AGLE-102. Abilitech Medical Inc.: A medical-device startup that launched Abilitech Assist, a wearable technology designed to aid individuals with limited arm movement. Fortinet: A leader in enterprise cybersecurity with significant exits. Viagene: A pioneer in gene therapy. Isis Pharmaceuticals: Known for antisense therapy (now Ionis Pharmaceuticals).
Common questions
What to know about DEFTA Partners
Upseed classifies DEFTA Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.